On July 15, 2025, Dermata Therapeutics held its Annual Meeting, where stockholders elected two directors, approved an auditor, and passed multiple proposals including a reverse stock split plan. Notably, the Issuance and Inducement Proposals received majority approval, reflecting positive shareholder sentiment.